Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Net Income (2017 - 2025)

Historic Net Income for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to -$130.1 million.

  • Crinetics Pharmaceuticals' Net Income fell 6932.76% to -$130.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$422.7 million, marking a year-over-year decrease of 5482.52%. This contributed to the annual value of -$297.4 million for FY2024, which is 4218.87% down from last year.
  • According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' Net Income is -$130.1 million, which was down 6932.76% from -$115.7 million recorded in Q2 2025.
  • Crinetics Pharmaceuticals' Net Income's 5-year high stood at -$22.9 million during Q1 2021, with a 5-year trough of -$130.1 million in Q3 2025.
  • Its 5-year average for Net Income is -$60.8 million, with a median of -$53.4 million in 2023.
  • As far as peak fluctuations go, Crinetics Pharmaceuticals' Net Income tumbled by 2023.15% in 2023, and later crashed by 6932.76% in 2025.
  • Quarter analysis of 5 years shows Crinetics Pharmaceuticals' Net Income stood at -$30.8 million in 2021, then crashed by 48.18% to -$45.7 million in 2022, then fell by 22.53% to -$55.9 million in 2023, then plummeted by 43.69% to -$80.4 million in 2024, then crashed by 61.85% to -$130.1 million in 2025.
  • Its Net Income stands at -$130.1 million for Q3 2025, versus -$115.7 million for Q2 2025 and -$96.6 million for Q1 2025.